mRNA-based COVID-19 vaccines

Overview

mRNA-based COVID-19 vaccines are a class of prophylactic vaccines that use messenger RNA encoding the SARS-CoV-2 spike protein, delivered in a formulation designed to enable host cells to transiently produce the antigen and thereby stimulate adaptive immune responses. In practice, this platform was developed rapidly during the COVID-19 pandemic and became a major component of global vaccination efforts because of its ability to induce strong protection against severe disease, hospitalization, and death.

Biologically, these vaccines rely on the host’s translational machinery rather than on live virus or purified protein antigen. After administration, the mRNA is taken up by cells, translated into spike protein, and the resulting antigen is presented to the immune system, promoting both antibody and T-cell responses. The platform has also driven new analytical and clinical research, including studies of vaccine hesitancy, booster uptake, immune monitoring in people with multiple myeloma, and evaluation of antigen expression using advanced mass spectrometry methods.

Focus of Latest Publications

Recent publications have examined mRNA-based COVID-19 vaccines from several complementary angles: public acceptance, clinical effectiveness, immune monitoring, and safety questions.

One line of research focused on vaccine hesitancy and disparities in socially vulnerable Latinx communities in North Texas. The publication noted that, in the United States, COVID-19 vaccines are widely available, but vaccine hesitancy and vaccine disparities remain. This work situates mRNA-based COVID-19 vaccines within a broader public health context, emphasizing that access alone does not ensure uptake and that social vulnerability can shape vaccination behavior.

Another article, titled mRNA COVID-19 vaccines: science versus misinformation, framed the rapid development of COVID-19 vaccines through Operation Warp Speed as an extraordinary triumph of scientific innovation. The publication highlighted that multiple vaccine platforms demonstrated remarkable efficacy in preventing severe disease, hospitalization, and death, ultimately saving millions of lives. In this context, mRNA-based COVID-19 vaccines were presented as a central example of modern vaccine science and as a target of misinformation that can influence public perception and acceptance.

Clinical monitoring of vaccination in immunocompromised populations was also represented. A study in Blood Advances assessed decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in people with multiple myeloma. At baseline, 55% of patients reported a history of COVID-19 infection and had received a median of 4 SARS-CoV-2 vaccines. This indicates that mRNA-based COVID-19 vaccines were part of repeated booster strategies in a high-risk hematologic population, where ongoing surveillance of outcomes is especially important.

At the laboratory level, a study in Analytical Chemistry addressed the need for robust methods to quantify antigen expression in the setting of mRNA vaccines. The emergence of mRNA vaccines created a new and pressing need for such methods, underscoring that the platform’s biological activity depends on measurable spike protein expression after delivery. This research supports the analytical infrastructure needed to evaluate mRNA-LNP formulations and to profile immune responses.

Safety surveillance was also explored in pediatrics. A study in Annals of Epidemiology examined the association between mRNA-based COVID-19 vaccination and the risk of autoimmune diseases in the pediatric population. The publication noted that the introduction of mRNA-based COVID-19 vaccines renewed attention to this question, given theoretical mechanisms such as molecular mimicry and immune overactivation. The study context reflects ongoing evaluation of rare or suspected adverse outcomes, particularly in children.

Finally, a household survey in Central-Western Brazil investigated vaccine hesitancy and information sources. More than half of participants hesitated to get vaccinated, and COVID-19 vaccines were the most hesitated. This reinforces that mRNA-based COVID-19 vaccines, despite their clinical importance, remain subject to hesitancy shaped by age, communication channels, and trust in information sources.

Across these studies, mRNA-based COVID-19 vaccines were not treated as a single uniform intervention but as a platform intersecting with public health communication, booster policy, immune response measurement, and safety assessment in both general and vulnerable populations.

Key Publications

• May mRNA COVID-19 vaccines: science versus misinformation. (RNA (New York, N.Y.), 2026, PMID 41850696): "The rapid development of COVID-19 vaccines as a result of Operation Warp Speed represented an extraordinary triumph of scientific innovation, with multiple vaccine platforms demonstrating remarkable efficacy in preventing severe disease, hospitalization, and death-ultimately saving millions of lives."
• May Factors influencing COVID-19 vaccine hesitancy in socially vulnerable Latinx communities in North Texas. (Human vaccines & immunotherapeutics, 2026, PMID 42132838): "In the United States, COVID-19 vaccines are widely available, but vaccine hesitancy and vaccine disparities remain."
• May Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma. (Blood advances, 2026, PMID 41734388): "At baseline, 55% of patients reported a history of COVID-19 infection and had received a median of 4 SARS-CoV-2 vaccines."
• May Age and vaccine information sources drive vaccine hesitancy: A household survey in Central-Western Brazil. (PloS one, 2026, PMID 42085451): "Over half of the participants hesitated to get vaccinated (50.2%), with the COVID-19 vaccines being the most hesitated (55.4%)."
• May High-Throughput Quantification of Spike Protein Expression by LC-MS for mRNA-LNP Evaluation and Immune Response Profiling. (Analytical chemistry, 2026, PMID 42023645): "However, the emergence of mRNA vaccines has created a new and pressing need for robust methods to quantify antigen expression."
• May mRNA-based COVID-19 vaccination and risk of autoimmune diseases in the pediatric population. (Annals of epidemiology, 2026, PMID 41831745): "The introduction of mRNA-based COVID-19 vaccines renewed attention to this question, given theoretical mechanisms such as molecular mimicry and immune overactivation."